News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab
Photo from Polyak Lab/Twitter
Sep 11, 2023, 00:27

Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. – Polyak Lab

Polyak Lab recently shared on X/Twitter:

“Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for TNBC is out in Molecular Cancer Therapeutics today. Congrats to all the coauthors! And of course a lot more to be explored in the future.”

Our preclinical study evaluating the efficacy of BRD4 inhibitor+Paclitaxel+anti-PD-L1 combination for Triple negative breast cancer is out in Molecular Cancer Therapeutics today. - Polyak Lab

For the article click here.
Source: Polyak Lab/Twitter

anti-PD-L1 BRD4 inhibitor cancer Molecular Cancer Therapeutics OncoDaily Oncology Paclitaxel Polyak Lab TNBC
Special Coverage
Science
Feb 22, 2025, 11:28
Myeloma Paper of the Day, February 22nd, suggested by Robert Orlowski
Blog
Feb 22, 2025, 11:22
Yan Leyfman: Great experience speaking at the NSHSS Pre-Medicine Workshop
Insight
Feb 22, 2025, 11:15
Henrik Ullum: The urgent need to protect WHO is also an opportunity
Oncolibrary
Feb 22, 2025, 11:02
New Paper Alert: Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer
Blog
Feb 22, 2025, 10:57
Tsetsegsaikhan Batmunkh: Factsheets for parents on childhood cancers and essential medicines in the Mongolian
Blog
Feb 22, 2025, 10:47
Akhilesh Bind: Advancing political leadership for equitable cancer care
Blog
Feb 22, 2025, 10:41
Nominations close for the 2025 Szent-Györgyi Prize for Progress in Cancer Research - NFCR
Blog
Feb 22, 2025, 06:28
Michael Sapienza: Breaking the stigma associated with CRC screening with Lead From Behind
Blog
Feb 22, 2025, 05:23
Sanam Loghavi: Excited to see the draft agenda for the inaugural Women in Hematology meeting
Blog
Feb 22, 2025, 05:18
Francisco J. Esteva: The clinical applications of PARPi across various cancers
Blog
Feb 22, 2025, 05:15
Eric K. Singhi: Not all EGFR mutations are the same
Dialogues
Feb 22, 2025, 05:05
ASCO24 Updates: Dr. Tycel Phillips on Glofitamab in Mantle Cell Lymphoma